Advertisement
Advertisement
U.S. Markets open in 2 hrs 10 mins
Advertisement
Advertisement
Advertisement
Advertisement

Sierra Oncology, Inc. (SRRA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
54.990.00 (0.00%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close54.99
Open54.98
Bid0.00 x 2900
Ask0.00 x 1200
Day's Range54.98 - 55.01
52 Week Range14.91 - 55.19
Volume858,299
Avg. Volume411,914
Market Cap827.874M
Beta (5Y Monthly)0.57
PE Ratio (TTM)N/A
EPS (TTM)-7.16
Earnings DateMar 09, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.00
  • Business Wire

    Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

    SAN MATEO, Calif., June 17, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib, an ACVR1 / ALK2, JAK1 and JAK2 inhibitor in development for the treatment of myelofibrosis.

  • Business Wire

    Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting

    SAN MATEO, Calif., May 26, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3-7, 2022, in Chicago and online. An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemi

  • Business Wire

    Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

    SAN MATEO, Calif., May 12, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the European Hematology Association (EHA). An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemic has been selected for oral presentation. Addition

Advertisement
Advertisement